BMS-986408 is a small molecule drug developed by Bristol-Myers Squibb Pharmaceuticals Ltd.

HLX14, a biosimilar candidate for PROLIA/XGEVA (denosumab), has been accepted by the US Food and Drug Administration (FDA).

we will use the drug Amisulpride as an example to demonstrate how to quickly obtain information about its chemical structure and patent situation using the Patsnap Chemical.

BridgeBio Oncology Therapeutics (BBOT) reports that the first patient has been treated with BBO-10203, a novel RAS:PI3Kα inhibitor.

Nedosiran, also known by its brand name RIVFLOZA, is an innovative RNA interference (RNAi) therapeutic developed by Dicerna Pharmaceuticals.

Three Phase 3 studies have begun using Datopotamab Deruxtecan combinations in patients with advanced nonsquamous non-small cell lung cancer.

Apixaban is a small molecule drug that targets factor Xa and has been approved for the treatment of various therapeutic areas.

Alterome Therapeutics has dosed the first patient in its Phase 1 trial of ALTA2618 for AKT1 E17K-mutant solid tumors (AKTive-001).

Tivanisiran is an innovative small interfering RNA (siRNA) therapeutic agent developed by Sylentis, a Spanish biopharmaceutical company specializing in RNAi technology.

Eisai showcases new clinical results indicating that the anti-MTBR tau antibody E2814 may block tau propagation at the 17th CTAD conference on Alzheimer's clinical trials.

Laroprovstat(AZD-0780) is a small molecule drug developed by AstraZeneca PLC, targeting the PCSK9 protein.

Bitterroot Bio has confirmed the conclusion of participant enrollment for its Phase 1 trial assessing BRB-002 in healthy subjects.